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Although tobacco smoking is very common among people with schizophrenia and
has devastating effects on health, strategies to ameliorate the risk are lacking. Some
studies have reported promising results yet quit rates are much lower than in the general
population. There is a need to advance research into smoking cessation efforts among
people with schizophrenia. We posed the following question to five leading international
experts in the field: “What are the top three research ideas we need to prioritize in order
to advance the field of reducing smoking amongst people with schizophrenia?” They
identified three broad priorities: (i) deeper understanding about the relationship between
smoking, smoking cessation and symptomatology; (ii) targeted, adaptive and responsive
behavioral interventions evaluated with smarter methodologies; and (iii) improvements in
delivery of interventions. Efforts should be made to establish a collaborative international
research agenda.
Keywords: smoking, smoking cessation, schizophrenia, research, health priorities, severe mental illness, mentally
Ill persons, vulnerable population
INTRODUCTION
We live in an era when tobacco, which is one of the most harmful substances for human health,
is legal and widely available in combustible form. Whilst tobacco control strategies have greatly
reduced smoking rates among the general population in high income countries, smoking rates
among people with schizophrenia remain very high [e.g., (1, 2)]. Schizophrenia is often complicated
by physical comorbidities and substance use (1). That well over half of people worldwide with
a diagnosis of schizophrenia smoke, should be (1) of great concern (given our knowledge of the
effects of smoking on quality of life, morbidity and mortality) and (2) a dynamic area of research
(given the often intractable nature of schizophrenia and what its relationship with smoking might
tell us). Sadly, neither of these are true and up until recently, little attention was paid to this issue.
We (AB, BB and DC) asked leading researchers from Australia, the UK and the USA the following
question, “What are the top three research ideas we need to prioritize in order to advance the field
of reducing smoking amongst people with schizophrenia?” Their views represent opinion rather
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than systematic review, and are provided below, followed by our
commentary.
THE PERSPECTIVE OF A SOCIAL WORK
CLINICIAN AND MENTAL HEALTH CARER
(AUSTRALIA)
Professor Sharon Lawn’s top three research ideas are drawn from
her experiences in the past 20 years of undertaking ethnographic
research, being a community-based clinician observing (at close
quarters and over extended periods) the lives of people with
schizophrenia, and from living with a smoker with schizophrenia.
Understanding More About the Overlap
Between Symptoms of Schizophrenia and
Withdrawal
We need to understand more about how the experience of
schizophrenia and the experience of nicotine dependence and
withdrawal interact with each other, at the basic level of “the
science” right through to the person’s day-to-day attempts to
manage the two. Many of the interventions proposed focus on
mental illness symptoms and nicotine dependence/withdrawal
as separate processes rather than investigating how the person
navigates the two at the levels of symptoms, pharmacotherapy
and subjective experience. I flagged this need a long time ago
(3), calling for the integration of care to recognize and treat
psychosis and nicotine withdrawal together. The problem is
that research, and then clinical practice, has resorted to offering
standard quit strategies and nicotine replacement therapy (NRT)
use. Outcomes of these interventions have lagged for smokers
with schizophrenia and sustaining quit status has been elusive.
People with schizophrenia tend to relapse quickly to smoking
because schizophrenia is a condition that is lived with every
day, is changeable and complex to manage and—in the absence
of support that addresses symptoms and dependence together—
reaching for a cigarette becomes the default option for coping.
Prevention and Early Intervention
Once the person becomes a smoker, a complex interplay of need,
coping, psychological, and physiological interactions between
their mental health and their smoking is established and becomes
insidiously reinforced. Also, from the carer’s perspective, there
is overwhelming frustration and sadness as the smoker ages
prematurely, trying to battle multimorbidity, and dying before
their time. Therefore, research must focus on prevention and
early intervention for people at risk and those with emerging
psychosis, so that they never become smokers in the first place,
or that they quit early.
Targeted Pharmacotherapies and Practical
Quit Strategies
Finally, we need more efficacious smoking cessation
interventions that take account of the knowledge gained frommy
first identified priority (above). This includes pharmacological
treatments that are safe and effective, as well as interventions
that provide real support to the person “in the moment,”
not just sending them away with NRT and brief counseling.
Interventions that involve quit strategies that are predominantly
“abstract” (e.g., weighing up the pros and cons, planning and
identifying a range of strategies) have limits for many people
with schizophrenia and are likely to be completely useless in
the moments of escalating stress and distress when the person
is unable to “call to mind” the reasoning that underlies such
abstract quit strategies. It may in fact escalate the person’s
anxiety, demanding clarity of thinking when thinking through
options is at its most difficult. Additionally, repeated failure
reinforces feelings of hopelessness. This is why apps that help
address “the moments” in the “here and now” without the need
to work out how to operationalise abstract concepts, are also
worth further research.
THE PERSPECTIVE OF A CLINICAL
PSYCHOLOGIST / CO-DIRECTOR OF A
COMPLEX TRAUMA AND RESILIENCE
RESEARCH UNIT, GREATER
MANCHESTER MENTAL HEALTH NHS
FOUNDATION TRUST (UK)
Dr. Sandra Bucci’s top three ideas are drawn from her clinical
and research experience focusing on psychological treatments of
people diagnosed with schizophrenia, those in the early stage of
psychosis and young people at ultra-high risk of psychosis.
Research Needs to Acknowledge Clinical
Complexity and Treatment Should Aim for
Realistic Goals Chosen by Patients
Asking people with a severe mental health problem to give up
or reduce smoking is complex. Researchers more often than not
argue that the ultimate goal for someone with a diagnosis of
schizophrenia should be cessation (4). However, motivational
problems, self-medication, being part of a social group, the
physiological effects associated with nicotine intake, and health
and social inequalities apparent in people with severe mental
health problems are just a few of the factors that influence the
complex interaction between smoking and mental health. It may
therefore be preferable to encourage patients to set realistic goals,
working toward cessation.
Providing Digital Technologies to Impact
on Daily Living and Newer Methodologies
Many programs target smoking behaviors in people with severe
mental health problems, with varied outcomes. We can provide
smokers all the information they need regarding the negative
health effects of smoking.We can also attempt to replace smoking
behaviors with other, more adaptive strategies during times of
stress. However, these approaches in and of themselves are
limited as they do not impact people in-the-moment, at the
time the smoker experiences a craving and is in most need of
support. There is a mismatch between the rather static nature
of providing support for smoking cessation to people who often
find it difficult to resist cravings and urges to smoke, and stressors
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that are momentary and contextual (5). This is where the digital
revolution, primarily through the availability of smartphones and
smartphone apps, may help. We must leverage the opportunities
digital technology afford, by developing intervention packages
that can be delivered in the moment, in the context in which
stressors occur. Digital technologies provide an unprecedented
opportunity to reach people in a timely manner in the context
of their daily life. There is a narrowing gap in smartphone
ownership in individuals with a diagnosis of schizophrenia (6),
highlighting the potential for healthcare programs targeting
smoking behavior to be taken from the clinic to people’s personal
environment, unconstrained by location and time.
Methodologies such as Just In Time Adaptive Interventions
(JITAI) that use digital technology as the modality for
intervention delivery, may be the optimal platform to provide
timely, contextual, in-the-moment support to people who find
it difficult to recall or use treatment strategies during stressful
moments where pressures on cognitive load and resources are
most intense (5). JITAI can provide the right type and amount of
support, at the right time by adapting to the individual’s changing
internal and contextual state (7). This approach is particularly
well-suited to delivering smoking cessation/reduction programs
among people with schizophrenia, affording us the opportunity
to prompt and nudge people at the time they are most vulnerable.
Developing evidence-based interventions that are rapidly
available and accessible at the population level are a priority.
Historically, researchers have relied on using randomized
controlled trials (RCTs) to explore the effectiveness of smoking
cessation/intervention programs. However, RCTs are time
consuming and do not in fact tell us which aspects of the
intervention are effective. In standard RCTs, the intervention is
typically fixed at trial onset and does not evolve over the course
of the trial. As we move toward using digital technologies to
nudge and prompt people regarding smoking behaviors in-the-
moment, we run the risk that the technology is outdated or even
obsolete at the end of the trial period. Adaptive approaches to
clinical trials should explore the implementation of more rapid
trial designs to ensure effective interventions are available in a
timely and accessible way (8).
Staff Attitudes
Thirdly, to ensure effective dissemination of effective programs,
we need more research into how best to change staff attitudes
to smoking cessation in mental health settings. Staff can be
reticent to encourage people with severe mental health problems
to quit smoking. The success of smoking cessation programs is
influenced not by patient uptake, but also clinician views and
attitudes about smoking behaviors.
THE PERSPECTIVE OF RESEARCHERS IN
TOBACCO ADDICTION (UK)
In their perspective, Dr. Debbie Robson combines experience
in mental health nursing and research in tobacco addiction
with that of Professor Ann McNeill, who has led numerous
research and policy initiatives to reduce smoking among those
with mental illness.
We Don’t Know Enough About the
Relationship Between Smoking and
Schizophrenia
Why is the relationship so strong? Evidence has been found
for shared familial and genetic risk factors, limited evidence
for schizophrenia causing people to smoke, and limited
evidence for smoking causing schizophrenia (9, 10). Research is
hampered by poor routine surveillance of smoking prevalence,
in contrast to internationally agreed robust measures used
to track smoking in general populations. There is a paucity
of large longitudinal studies exploring causal mechanisms,
assessing frequency/heaviness of smoking, nicotine intake,
quitting behaviors, and detailed objective measurement of the
mental illness and their interactions.
We Have Failed to Identify Appropriate
Ways Out of Tobacco Addiction for People
With Schizophrenia
Tobacco control and smoking cessation interventions are usually
derived/adapted from evidence generated in general population
samples (11). Very few are co-designed by smokers with
schizophrenia. Although the outcomes from using existing
evidence-based treatments for smoking cessation could be
improved by finding ways to promote better adherence, people
with schizophrenia deserve investment to develop bespoke
interventions tailored to their illness-related psychological,
cognitive, and social needs (12). For example, we should
ascertain what outcomes smokers with schizophrenia value most
and what treatments are acceptable. We then need to co-
design interventions with people with schizophrenia and key
stakeholders.
A Lack of Engagement of the Health
Workforce
People with lived experience of schizophrenia have more
frequent contact with health services (13) and a visit to a
hospital inpatient/outpatient setting should be an opportune
time to promote key messages about smoking and offers
of support to quit. This is undermined by poor knowledge
and therapeutic nihilism (14) among health professionals and
resistance to implementing comprehensive smokefree policies
(15). Improving the capability of the health workforce so that
every clinician is committed to and has the competence to
initiate conversations and support those with lived experience
of schizophrenia to quit smoking, is vital. We need to develop
and evaluate novel ways to integrate smoking and tobacco
dependence treatment, education and training into routine
healthcare.
THE PERSPECTIVE OF A CLINICAL
PSYCHOLOGY RESEARCHER WITH A
SPECIAL INTEREST IN ENHANCING
MOTIVATION TO CHANGE (USA)
Dr. Marc Steinberg (16–23) has a long-standing interest in
researching smoking cessation treatments among people from
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socially disadvantaged backgrounds, including people with
schizophrenia.
Evaluating How to Best Address Reduced
Distress Tolerance/Task Persistence in
This Population
Given low abstinence rates, we should consider additional
behavioral supports to combine with empirically supported
pharmacological approaches. Smokers with schizophrenia have
reduced task persistence/distress tolerance as compared to
smokers without psychiatric comorbidity (16–18), and this
may be a fertile target for counseling. Approaches such
as traditional cognitive behavior therapy (CBT) focusing on
thoughts related to persistence or distress tolerance, and
Acceptance and Commitment Therapy (ACT) focusing on
increasing psychological flexibility should be examined in this
population. As Baker (19) recently suggested, the field should
consider factorial designs to determine optimal counseling
components for people with schizophrenia, and to empirically




While smokers with schizophrenia report being as interested in
quitting as their peers without psychiatric comorbidity (20), the
field needs to do better in increasing the number of quit attempts,
and, importantly, increasing the number of appropriately aided
quit attempts. An empirically validated approach likely to be
useful in this endeavor is Motivational Interviewing (MI) (21).
Adaptations of MI can support quit attempts as well as tobacco
dependence treatment seeking in smokers with schizophrenia
(21, 22). The literature on MI for smokers with schizophrenia
is sparse, however, with many important questions remaining
unanswered. Future studies should examine MI not only for
motivating quit attempts, but also enhancing such attempts.
Training Providers to Address Tobacco Use
Finally, the field should strive to increase the number of
quit attempts by encouraging the healthcare system to address
tobacco use in their patients. In addition to providing and
evaluating continuing education opportunities, we must increase
the number of graduate programs and medical schools that
include tobacco dependence treatment in their curricula because
preliminary evidence suggests that training behavioral healthcare
providers improves the chances of their addressing tobacco in
their patients (23).
DISCUSSION
Three broad areas were highlighted as priorities for research
by our invited experts. The contributions by Lawn and also
by Robson and McNeill call for more understanding about
the relationship between smoking, smoking cessation and
symptomatology, ranging from large longitudinal datasets
to monitoring interactions between smoking and symptoms.
Intriguingly, two smoking cessation studies among people
with schizophrenia recently conducted by the current
authors (24–26), in the US and Australia, have found that
face-to-face or telephone-delivered interventions with core
components consisting of monitoring psychiatric symptoms and
understanding medication interactions with tobacco smoking
appear promising. In this issue, we1 describe the “Quitlink”
randomized controlled trial, in which such components will be
delivered via quitline.
The second major area for further research was in the area
of behavioral interventions. Better preventive measures, early
interventions and motivational strategies tailored for people with
schizophrenia were seen as important by Lawn and Steinberg.
Bucci and Steinberg highlighted the complexity of presentations
that take into account specific aspects of schizophrenia that
are likely targets of intervention (e.g., distress tolerance and
also flexible goals toward smoking cessation). Lawn and Bucci
argue strongly for more research into interventions which can
be used by smokers with schizophrenia in everyday settings, to
strengthen the likelihood of them being able to address smoking
in challenging situations. Bucci promotes digital interventions
but Lawn also notes the need for smarter medications which
could address both mental health and smoking. Bucci and
Steinberg both point to the need for new and emerging behavioral
interventions to require better and faster methodologies,
supporting identification of effective key components and faster
dissemination and adaptation to individual needs. Importantly,
co-design was noted by Robson andMcNeill as likely to yield vital
information about valued outcomes and interventions.
Thirdly, all experts lamented the paucity of smoking cessation
care provided by health systems and staff. Shifting health care
systems and culture, building the capacity and confidence of
clinical staff to address smoking and implementing smoke free
policies are challenging changes within organizations. Emerging
research however suggests that systems and organizational
change interventions may provide a sustainable approach to
integrating smoking cessation support in settings that care for
people with schizophrenia (27–29).
There are a few notable limitations of this paper. Topics
identified related mainly to high-income countries. Also, the
utility of existing yet contentious smoking cessation treatments
such as electronic cigarettes and varenicline was not explored.
The perspectives presented here provide a clear agenda
for further research. National and international research
collaborations (e.g., Mental health and smoking partnership2)
should target these priorities with a view to impacting upon the
very high rates of smoking among people with schizophrenia.
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